000291282 001__ 291282
000291282 005__ 20250401142757.0
000291282 0247_ $$2doi$$a10.1038/s41541-024-00914-z
000291282 0247_ $$2pmid$$apmid:38926425
000291282 0247_ $$2altmetric$$aaltmetric:166283428
000291282 037__ $$aDKFZ-2024-01365
000291282 041__ $$aEnglish
000291282 082__ $$a610
000291282 1001_ $$0P:(DE-He78)2d5634b584ebede249368464b907e28c$$aZhao, Xueer$$b0$$eFirst author$$udkfz
000291282 245__ $$aA safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity.
000291282 260__ $$a[London]$$bNature Publishing Group$$c2024
000291282 3367_ $$2DRIVER$$aarticle
000291282 3367_ $$2DataCite$$aOutput Types/Journal article
000291282 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1719495243_13583
000291282 3367_ $$2BibTeX$$aARTICLE
000291282 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291282 3367_ $$00$$2EndNote$$aJournal Article
000291282 500__ $$a#EA:D335#LA:D335#
000291282 520__ $$aPersistent infection with high-risk human papillomavirus (HPV) is widely recognized as the primary cause of cervical and other malignant cancers. There are six licensed prophylactic vaccines available against HPV, but none of them shows any significant therapeutic effect on pre-existing infections or lesions. Thus, a prophylactic vaccine also endowed with therapeutic activity would afford protection regardless of the vaccine recipients HPV-infection status. Here, we describe the refinement and further potentiation of a dual-purpose HPV nanoparticle vaccine (hereafter referred to as cPANHPVAX) relying on eight different HPV L2 peptide epitopes and on the E7 oncoantigens from HPV16 and 18. cPANHPVAX not only induces anti-HPV16 E7 cytotoxic T-cell responses in C57BL/6 mice, but also anti-HPV18 E7 T-cell responses in transgenic mice with the A2.DR1 haplotype. These cytotoxic responses add up to a potent, broad-coverage humoral (HPV-neutralizing) response. cPANHPVAX safety was further improved by deletion of the pRb-binding domains of E7. Our dual-purpose vaccine holds great potential for clinical translation as an immune-treatment capable of targeting active infections as well as established HPV-related malignancies, thus benefiting both uninfected and infected individuals.
000291282 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000291282 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291282 7001_ $$0P:(DE-He78)35b8b312f24f786ff12489e8b1cf05ee$$aZhang, Yueru$$b1$$udkfz
000291282 7001_ $$aTrejo-Cerro, Oscar$$b2
000291282 7001_ $$0P:(DE-He78)64cd63747c118ca6ccef366d50a24e03$$aKaplan, Ecem$$b3$$udkfz
000291282 7001_ $$0P:(DE-He78)4cbe3abf3c7df5d7fbac1c945e4c2fce$$aLi, Zhe$$b4$$udkfz
000291282 7001_ $$0P:(DE-He78)8d1951818cf55b795407fc19811d7b56$$aAlbertsboer, Femke$$b5
000291282 7001_ $$0P:(DE-He78)18b47c4ee10637bff8bd8b11d046972f$$aEl Hammiri, Neyla$$b6$$udkfz
000291282 7001_ $$0P:(DE-HGF)0$$aMariz, Filipe Colaço$$b7
000291282 7001_ $$aBanks, Lawrence$$b8
000291282 7001_ $$aOttonello, Simone$$b9
000291282 7001_ $$0P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aMüller, Martin$$b10$$eLast author$$udkfz
000291282 773__ $$0PERI:(DE-600)2882262-6$$a10.1038/s41541-024-00914-z$$gVol. 9, no. 1, p. 119$$n1$$p119$$tnpj vaccines$$v9$$x2059-0105$$y2024
000291282 8564_ $$uhttps://inrepo02.dkfz.de/record/291282/files/s41541-024-00914-z.pdf
000291282 8564_ $$uhttps://inrepo02.dkfz.de/record/291282/files/s41541-024-00914-z.pdf?subformat=pdfa$$xpdfa
000291282 8767_ $$8SN-2024-00560-b$$92024-08-20$$d2025-03-27$$eAPC$$jZahlung erfolgt
000291282 909CO $$ooai:inrepo02.dkfz.de:291282$$popenCost$$pOpenAPC$$pVDB
000291282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d5634b584ebede249368464b907e28c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000291282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)35b8b312f24f786ff12489e8b1cf05ee$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000291282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)64cd63747c118ca6ccef366d50a24e03$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000291282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4cbe3abf3c7df5d7fbac1c945e4c2fce$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000291282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d1951818cf55b795407fc19811d7b56$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000291282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)18b47c4ee10637bff8bd8b11d046972f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000291282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000291282 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000291282 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000291282 9141_ $$y2024
000291282 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ VACCINES : 2022$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:19Z
000291282 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:19Z
000291282 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:19Z
000291282 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:11:19Z
000291282 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ VACCINES : 2022$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-24
000291282 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-24
000291282 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000291282 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000291282 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000291282 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000291282 9202_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000291282 9200_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000291282 9201_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000291282 9201_ $$0I:(DE-He78)D130-20160331$$kD130$$lB-Zell-Immunologie$$x1
000291282 980__ $$ajournal
000291282 980__ $$aVDB
000291282 980__ $$aI:(DE-He78)D335-20160331
000291282 980__ $$aI:(DE-He78)D130-20160331
000291282 980__ $$aUNRESTRICTED
000291282 980__ $$aAPC